0001493152-26-022010
SEC filingOperating loss remained stable at -$1.9M (51.4% improved YoY) amid R&D pause, though net loss widened to -$1.9M (-16.0% YoY) without prior-year non-operating gains, as cash burn eased to -$1.6M but liquidity falls short of 12-month needs.
Matinas BioPharma reported an operating loss of -$1.9 million for Q1 2026, stable compared to -$1.9 million in the prior-year quarter with a 51.4% year-over-year improvement on a relative basis. This stability stems from a pause in the MAT2203 development program and headcount reductions, which curbed research and development expenses. These cost controls offset rising general and administrative expenses driven by higher legal and consulting fees, though partially mitigated by lower stock-based compensation and reduced headcount. Management notes that G&A expenses are anticipated to increase slightly in 2026 as the corporate strategy evolves, reflecting ongoing operational shifts in this clinical-stage biopharma company.
Net income deteriorated to a loss of -$1.9 million from -$1.7 million year-over-year (-16.0% change), with diluted EPS improving modestly to -$0.30 from -$0.33 (9.1% YoY). The wider net loss reflects the absence of non-operating gains, such as prior-year warrant liability benefits, that had partially offset operating shortfalls. Without these tailwinds, core operating dynamics dominated, underscoring the company's pre-revenue status and reliance on cost management for loss mitigation. Investors should note this highlights the volatility inherent in biotech financials where non-cash items can significantly influence bottom-line results.